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With a sharp increase in the cases of multi-drug resistant (MDR) bacteria all over the
world, there is a huge demand to develop a new generation of antibiotic agents to fight
them. As an alternative to the traditional drug discovery route, we have designed an
effective antibacterial agent by modifying an existing commercial antibiotic, kanamycin,
conjugated on the surface of gold nanoparticles (AuNPs). In this study, we report a
single-step synthesis of kanamycin-capped AuNPs (Kan-AuNPs) utilizing the combined
reducing and capping properties of kanamycin. While Kan-AuNPs have increased
toxicity to a primate cell line (Vero 76), antibacterial assays showed dose-dependent
broad spectrum activity of Kan-AuNPs against both Gram-positive and Gram-negative
bacteria, including Kanamycin resistant bacteria. Further, a significant reduction in the
minimum inhibitory concentration (MIC) of Kan-AuNPs was observed when compared
to free kanamycin against all the bacterial strains tested. Mechanistic studies using
transmission electron microscopy and fluorescence microscopy indicated that at least
part of Kan-AuNPs increased efficacy may be through disrupting the bacterial envelope,
resulting in the leakage of cytoplasmic content and the death of bacterial cells. Results
of this study provide critical information about a novel method for the development of
antibiotic capped AuNPs as potent next-generation antibacterial agents.
Keywords: gold nanoparticles, kanamycin, antibiotic resistance, antibacterial activity, characterization
INTRODUCTION
Since the discovery of the first antibiotic, Penicillin, in 1928 (National Historic Chemical
Landmarks program, 1999) the process of developing mechanisms of resistance against
various synthetic antibiotics has been initiated in bacteria. This is evident from the presence
of various resistant bacterial strains in the early 1930s and 1940s (Clatworthy et al.,
2007; “News Feature: A Call to Arms”, 2007). Moreover, widespread and irrational use
of antibiotics across the globe has led to the emergence of antibiotic resistant strains of
bacteria. A number of bacterial strains are even resistant to multiple antibiotics, known as
multi-drug resistant (MDR) bacterial strains (Jugheli et al., 2009; Arias and Murray, 2012;
Bennadi, 2013; Laxminarayan et al., 2013; Sutradhar et al., 2014; WHO | Antimicrobial
Resistance, 2014; “Antibiotic Resistance: An Ecological Perspective on an Old Problem” , 2015;
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“Antibiotic Resistance Threats in the United States, 2013”,
2015; World Health Organization [WHO], 2015). Currently
the rate at which bacteria are developing resistance to
existing antibiotics is faster than the development of newer
antibiotics (“World Economic Forum – Global Risks 2013
Eighth Edition”, 2014). Several strategies are being employed
to develop novel antibacterial agents or to potentiate the
activity of currently existing/commercially successful antibiotics
(Tillotson and Theriault, 2013). One of the most widely
researched approaches involves the use of metallic and
metal-oxide nanoparticles (1–100 nm), such as gold (Au),
silver (Ag), and zinc oxide (ZnO) to enhance bactericidal
activity (Seil and Webster, 2012; Chernousova and Epple,
2013).
Among various inorganic nanomaterials, gold nanoparticles
(AuNPs) have gained immense attention for the design and
development of innovative biomedical tools (Bao et al., 2013;
Drbohlavova et al., 2013; Jiang et al., 2013; Khan et al.,
2013; Khlebtsov et al., 2013; Kumar et al., 2013; Zhao and
Jiang, 2013; Zhang et al., 2013; Zhou et al., 2013; Liao et al.,
2014; Shah et al., 2014). AuNPs have a number of inherent
features, such as biosafety (Finkelstein et al., 1976; Stanier, 2014),
ease of functionalization (Tiwari et al., 2011), facile synthesis
(Akhtar et al., 2013; Shah et al., 2014; Shedbalkar et al., 2014),
large surface/volume ratio allowing the release of high drug
payload at infected sites (Voliani et al., 2012), multiple-targets of
bactericidal action (Tillotson and Theriault, 2013), and an ability
to penetrate biological membranes (Voliani et al., 2012; Tillotson
and Theriault, 2013), which make them strong candidates for
the development of novel antibacterial agents. Despite the fact
that AuNPs are strong candidates for antibacterial agents, AuNPs
have been much more widely utilized as nanoparticles for cancer
therapy (Ahmad et al., 2013; Drbohlavova et al., 2013; Almeida
et al., 2014), while less extensive efforts have been made in the
field of antibacterial agents (Zhao and Jiang, 2013). Complicating
the utilization of AuNPs for antibacterial treatment is the fact that
common methods of synthesis involve multiple steps, use toxic
organic chemicals, and occur under harsh reaction conditions,
all of which could have detrimental effects on biological systems
(Burygin et al., 2009; Zhao et al., 2010; Bhattacharya et al.,
2012; Brown et al., 2012; Zhou et al., 2012; Lima et al.,
2013).
Kanamycin is an aminoglycoside antibiotic with broad
spectrum activity that inhibits bacterial protein synthesis
(Umezawa, 1958). High water-solubility (50 mg/mL) and absence
of delayed toxicity are some of the additional advantages of
kanamycin over other actinomycete-derived antibiotics (Xie
et al., 2011). Here, we attempt to potentiate the antibacterial
activity of kanamycin by designing a unique formulation of
kanamycin capped gold nanoparticles (Kan-AuNPs) using a
simple, kanamycin-mediated, bio-friendly synthesis that we have
developed (Dakshinamurthy and Sahi, 2012; Pender et al., 2013).
To this end we established and fine-tuned the synthesis protocol
by determining the optimum concentrations of nucleating
agent [potassium gold (III) chloride (KAuCl4)], and reducing
agent (kanamycin sulfate) to yield stable, monodispersed
Kan-AuNPs. The resultant Kan-AuNPs were morphologically
characterized by various analytical and spectroscopic techniques.
The Kan-AuNPs were then evaluated for their antibacterial
activity against multiple bacterial strains. Kan-AuNPs showed
a significant improvement in efficacy against both susceptible
and resistant Gram-positive and Gram-negative bacterial strains
as compared to pure kanamycin. Finally, electron microscopy
revealed that Kan-AuNPs localized on the entire surface of
the bacterial cell envelope eventually resulting in bacterial
lysis. The results demonstrate a successful development of
a highly efficient antibiotic-AuNP against several infectious
bacterial strains suggesting a novel strategy to combat MDR
bacteria.
MATERIALS AND METHODS
Materials
Analytical grade kanamycin sulfate (Calbiochem, EMD
Chemicals), potassium gold(III) chloride (Sigma Aldrich),
sodium citrate dihydrate (Sigma Aldrich) Luria-Bertani (LB)
broth, (Novagen, EMD Biosciences), Tryptic soy (TS) broth
(Teknova), Lennox LB agar, [Beckton, Dickson (BD) and Co.],
TS agar (BD and Co.), XTT (Biotrium), Menadione (Spectrum
chemicals), and propidium iodide (Calbiochem) were purchased
and used as required. All laboratory glassware was thoroughly
cleaned and rinsed followed by steam sterilization (121◦C,
45 min) before use. The bacterial organisms Staphylococcus
epidermidis (ATCC #12228), Streptococcus bovis (ATCC #
9809), Enterobacter aerogenes (ATCC # 13048), Pseudomonas
aeruginosa PA01, P. aeruginosa UNC-D (Lawrenz et al., 2015),
Yersinia pestis CO92 LuxPtolC pCD1(−) (Sun et al., 2012), and
Y. pestis CO92::Km LuxPtolC pCD1(−) (Y. pestis CO92 LuxPtolC
pCD1(−) with unresolved Kan resistance cassette) were cultured
by standard procedures.
Biofriendly Synthesis of Kanamycin-Gold
Nanoparticles (Kan-AuNPs)
1.72 mM kanamycin sulfate dissolved in an M9 minimal
media buffer (pH 7.2 ± 0.2) was heated to 80◦C and aqueous
KAuCl4 was added to achieve a final concentration of 0.79
mM KAuCL4. The mixture was incubated for 5 min and
then allowed to cool to room temperature. A colorimetric
shift from colorless to pink indicated the formation of Kan-
AuNPs. Unreacted kanamycin (Kan) was removed by at least five
cycles of washing and centrifugation (15,000 rpm for 20 min).
Following the final wash, Kan-AuNPs were pelleted, freeze-
dried, and stored at room temperature. Freeze dried Kan-AuNPs
were re-suspended in autoclaved nanopure water for subsequent
analysis.
Characterization of Antibiotic Coated
Nanoparticles
The size and shape of Kan-AuNPs was determined using a JEOL
JEM 1400 Plus transmission electron microscope (TEM) with
120 kV accelerating voltage. For analysis, 5 µL of Kan-AuNPs
suspension was placed on a 400-mesh formvar-coated copper
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grid and allowed to air-dry. Images of the selected regions were
taken using the built-in AMT XR-81M-B camera which were
later developed and processed via Capture Engine Software AMT
Version 602.600.52. The UV-Vis spectrum of probe sonicated
samples of Kan-AuNPs was determined using a Hitachi U-
3900 spectrophotometer at a resolution of 0.5 nm to observe
the peaks generated by the characteristic optical properties of
AuNPs known as surface plasmon resonance (SPR). Diameter
and average size distribution of the particles was determined
using a Zetasizer Nano S (Malvern Instruments Ltd.) dynamic
light scattering analyzer at 25◦C with a scattering angle of 90◦.
One mililiter of 2 mg mL−1 Kan-AuNPs suspension was probe
sonicated and the average of the three measurements involving
13 runs each were performed. Presence of Kan on the surface
of the AuNPs was confirmed from the surface elemental analysis
using a JEOL-JSM-6510 LV scanning electron microscope (SEM)
with IXRF system. Fifty microliter of 1 mg mL−1 sonicated
sample of Kan-AuNPs suspension was evenly spread on a
cleaned silicon wafer and dried under vacuum. SEM images of
substrate were obtained at 20 kV accelerating voltage and 5kX
magnification followed by surface elemental analysis using energy
dispersive spectroscopy (EDS). The presence and percentage of
Kan (w/w) was confirmed using thermo-gravimetric analysis
(TGA). Approximately 5 mg of lyophilized Kan-AuNPs and
pure Kan powder was heated individually in a platinum pan
over a temperature range of 25◦C to 850◦C at a heating rate
of 10◦C min−1 in the presence of nitrogen (N2) gas using a
TA Q5000 instrument. The N2 gas was changed to air after
650◦C to allow complete oxidation. A thermogram showing
the gradual weight loss of ligand upon heating of Kan-AuNPs
was plotted and compared to pure Kan. The electrostatic
charge and stability of the nanoparticles were determined using
a Zetasizer Nano S. A 1 mg mL−1 Kan-AuNP suspension
was prepared by dissolving the sample in a 10 mM NaCl
solution followed by filtration through a 0.1 µm pore size
filter. The pH of the solution was maintained at a pH of
7.2 ± 0.2 throughout the analysis. The analysis was performed
at 25 ± 0.3◦C, with an equilibration time of 2 min, and the
applied voltage was 100 V. Analysis was performed in triplicate to
verify the results (Nanotechnology Characterization Laboratory,
2009).
Synthesis and Characterization of
Citrate-AuNPs
For synthesis of citrate conjugated gold nanoparticles the
Turkevich method was employed (Turkevich et al., 1951). Briefly,
1 mM Aurochloric acid was preheated to 100◦C with a 1%
solution of sodium citrate dihydrate (Kimling et al., 2006).
A colorimetric shift from colorless to dark red was indicative
of the formation of Citrate-AuNPs. The reaction mixture was
allowed to cool to room temperature and the resulting solution
was titrated to a pH of 7.2 ± 0.2. Unbound reactants were
removed by washing with autoclaved nanopure water and
centrifugation (15,000 rpm for 20 min) five times. After the final
wash, Citrate-AuNPs were pelleted, lyophilized, and stored at
room temperature until resuspended for use. Citrate-AuNPs were
characterized by TEM and zeta potential as described above for
Kan-AuNPs.
Evaluation of Kan-AuNPs for
Antibacterial Activity
Twofold serial dilutions of the Kan, Kan-AuNPs, or Citrate-
AuNPs were made in a 96 well microtiter plate as previously
described (National Committee for Clinical Laboratory
Standards, 1999; Wiegand et al., 2008). Bacteria were grown
overnight and 3 × 105 colony forming units (CFU) were added
to each well. One well at each antibiotic concentration was
inoculated with medium alone as a sterility control. For the
positive growth control, the same volume of antibiotic was
replaced with equivalent amount of nutrient medium (National
Committee for Clinical Laboratory Standards, 1999). The plates
were statically incubated at 37◦C for 24 h. The minimum
inhibitory concentrations (MIC) were determined to be the
antibiotic concentration that completely inhibited bacterial
growth with respect to the positive control (National Committee
for Clinical Laboratory Standards, 1999). Each experiment was
performed in triplicate to verify the validity of the results. In
order to directly compare concentrations of antibiotic required
to inhibit growth, the MIC of Kan-AuNPs represents the
concentration of the Kan present in each well (as calculated using
the organic and inorganic compositional values determined
through TGA). When comparing Citrate-AuNPs to Kan-AuNPs,
the MIC represents the concentration of the gold present in each
well.
Cellular Cytotoxicity of Kan-AuNPs
To determine host cell cytotoxicity, 2 × 104 Vero 76 cells
in DMEM + 10% FBS were added to wells of a white
CellStar 96 well plate (Greiner Bio-One). 24 h later, the
medium was replaced with twofold serial dilutions of Kan-
AuNP in DMEM + 10% FBS (final concentrations from 0.002
to 5.0 mg ml−1) or Kan (final concentrations from 0.04 to
160 mg ml−1) and returned to the incubator. After 24 h,
10 µl of AlamarBlue (Invitrogen) was added and incubated
for 2 h. AlamarBlue fluorescence was determined using a
Synergy H1 plate reader (BioTek) and compared to untreated
Vero 76 cells. The cytotoxic concentration was calculated
using the log(inhibitor) vs. response equation in Graph Pad
Prism 5.
Evaluation of Interactions of Kan-AuNPs
with Bacteria
To visualize morphological changes in bacteria after inoculation
with Kan-AuNPs, cross-sections of bacteria were prepared with
the aid of ultra-microtome and observed under a TEM (Badwaik
et al., 2011, 2013). One mililiter of bacterial culture was incubated
at 37◦C, 150 rpm, for 12 h in the presence of the MIC of Kan-
AuNPs. The sample was then centrifuged (at 4,000 rpm, for
3 min) and the pellet was re-suspended in 1 mL of primary fixing
solvent (16% w/v paraformaldehyde and 10% w/v glutaraldehyde
in 50 mM sodium cacodylate buffer [pH ∼7.4]) and incubated
for 2 h. After incubation, bacteria were centrifuged and washed
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twice with cacodylate buffer. Bacteria were then re-suspended
in 1 mL of 1% osmium tetroxide solution (OsO4), and further
incubated for 1 h at 25◦C for post-fixation. Post-fixed samples
were treated with graded ethanol concentrations (25, 50, 75, 95,
and 100%) after washing with nanopure water. The dehydrated
samples were centrifuged and the pellets were infiltrated with
graded Spur’s epoxy resin (33, 66, 95, and 100 %) for an hour and
left overnight in 100% resin. The samples were then centrifuged
in BEEM R© capsules, which were solidified by heating at 70◦C
for 18 h. Using glass knives for RMC MT-X ultra-microtome,
ultra-thin sections of sample were cut and stained with 2%
aqueous uranyl acetate for 15 min and Reynold’s lead citrate
for 3 min. The samples were then imaged with a JEOL-100CX
TEM.
Bacterial membrane permeability was evaluated by propidium
iodide (PI) exclusion (Zhao et al., 2010). Bacteria were
incubated in the presence of the MIC of Kan-AuNPs for
∼12 h, washed with phosphate buffer saline (PBS) and
centrifuged (6000 rpm, 3 min) thrice. Washed bacteria
were incubated with 100 µM PI for 30 min in the dark.
After incubation, unbound PI was removed by washing the
sample with PBS. Ten microliter of the resulting suspension
was placed on a glass slide and covered with a cover
slip. The sample was viewed using a Leica fluorescence
microscope. Bacteria without Kan-AuNPs inoculation served as
the negative control. The number of permeable cells (showing red
fluorescence) was calculated as an average from three individual
measurements.
RESULTS AND DISCUSSION
Synthesis and Characterization of
Kan-AuNPs
One of the vital steps in the preparation of AuNPs is
the addition of chemical agents to reduce the gold ions
(Au3+/Au2+) to neutral gold atoms, which results in aggregation
upon reaching the saturation limit (Shah et al., 2014). In
traditional synthesis protocols a secondary capping agent
is then added to stabilize and restrict the size of gold
aggregates to the nanometer size range (Shah et al., 2014).
However, using such methods requires multiple steps to purify
the product of unwanted components, which results in the
overall process being expensive and labor intensive with
limited scalability. Furthermore, due to concerns regarding
the biological compatibility of the chemical agents used in
the synthesis process, there has been a recent emphasis on
finding biologically friendly methods for synthesizing AuNPs
(Shah et al., 2014). In this context we developed a simple,
single-step method for synthesizing antibiotic functionalized
FIGURE 1 | Illustration of the morphological characterization of synthesized Kan-AuNPs. (A) TEM micrograph showing the formation of well-dispersed
spherical Kan-AuNPs in the size range of 20 ± 5 nm. (B) UV-Vis spectra of Kan-AuNPs showing a strong absorption peak at 546 nm which is characteristic of
spherical AuNPs. (C) Plot showing average particle size distribution of Kan-AuNP suspension obtained using DLS (D) Energy dispersive spectroscopy (EDS) spectra
of Kan-AuNPs showing the presence of an elemental peak for carbon (C) and gold (Au) at 0.2 and 2.1 keV respectively. Figure in the inset shows SEM image of spin
coated sample of Kan-AuNPs on silicon chip obtained at an accelerating voltage of 20 keV with a magnification of 5 kX. (E) A comparison of thermo-gravimetric
(TGA) analysis showing loss of organic material for kanamycin (—) and Kan-AuNPs (- - -) respectively. The samples were heated from room temperature to 650◦C at
a rate of 10◦C min−1 under nitrogen flow followed by heating till 850◦C under air.
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AuNPs. Kan has electron rich hydroxyl and amine functional
groups which can serve as both a reducing and capping
agent. The optimum concentration of Kan and gold required
for AuNP synthesis was determined by assessing varying
concentrations of both Kan and KAuCl4 (data not shown).
Based on these analyses it was determined that 1.72 mM of
Kan and 0.79 mM of KAuCl4, when incubated in aqueous
buffer (pH ∼7.2 ± 0.2 heated to 80◦C), for 5 min, followed by
cooling to 37◦C, formed AuNP of uniform size and dispersion.
This synthesis protocol resulted in the optimal yield based
on the size and morphological character of Kan-AuNPs (see
below).
Qualitative analysis of aggregation behavior of nanoparticles
and morphological characteristics were studied using
TEM at 120 kV. Micrographs showed the particles to
be nearly spherical shaped and monodispersed with an
average diameter of 20 ± 5 nm (Figure 1A). A UV-
Vis spectrum of Kan-AuNPs recorded in the visible
region (400–850 nm) showed a peak absorption (λmax)
value at 546 nm (Figure 1B) which further supports the
size of AuNP obtained from TEM (Haiss et al., 2007;
Amendola and Meneghetti, 2009). Further, dynamic light
scattering (DLS) analysis of Kan-AuNPs showed a sharp
peak with an average size distribution of 20 ± 5 nm
(Figure 1C) which is in agreement with TEM and UV-Vis
data.
SEM-EDS analysis further defined the surface elemental
composition of Kan-AuNPs, where dense portions of the Kan-
AuNPs sample were selected and magnified during acquisition.
The electron beam was focused on the selected region to
obtain the localized elemental composition using IXRF software
and the final elemental composition was averaged from three
different regions of analysis. Results of the EDS spectral
analysis revealed the presence of elemental peaks for carbon
(C) and gold (Au) at ∼0.2 keV and ∼2.1 keV, respectively
(Figure 1D). The percent composition of carbon and gold
was found to be 16.65 and 66.55% respectively. Presence of
a gold peak ensured the formation of AuNPs whereas the
carbon peak confirmed the presence of the organic ligand
(Kan) on the surface of AuNPs. Thermo-gravimetric analysis
(TGA) of Kan-AuNPs was used to quantify the amount of
organic ligand (Kan) bound to the surface of AuNPs. This
measurement is essential to define the mass of Kan present
on the surface of Kan-AuNPs, and thus, allowing for direct
comparison between Kan and Kan-AuNPs in subsequent efficacy
trials. The weight percentage is also critical in calculating the
actual dose of drug for in vivo studies. From the thermogram,
we observed a 35% loss in the total mass of heated Kan-
AuNPs (Figure 1E). TGA of pure Kan was also performed for
reference as shown in Figure 1E. The similar decomposition
rates of Kan and the organic conjugate on the AuNPs
indicate that Kan is conjugated to the AuNPs and comprises
about 350 mg per 1.000 g of Kan-AuNP. Furthermore, the
surface zeta potential of the Kan-AuNPs was determine to be
+18.7 mV, indicating that the nanoparticles will readily interact
with negatively charged bacterial membranes (Ivanov et al.,
2009).
Kanamycin Conjugation to AuNPs
Improves Efficacy of the Antibiotic
against Both Gram-Negative and
Gram-Positive Bacteria
To determine whether AuNP conjugation increased the efficacy
of Kan, we measured the MICs of Kan-AuNPs for a panel
of bacterial species with varying degrees of resistance to Kan.
For our initial analysis we chose several bacteria available from
ATCC commonly used in the laboratory as controls for MIC
assays (S. bovis, S. epidermidis, E. aerogenes) and P. aeruginosa
PA01 and Y. pestis CO92. For each strain, Kan and Kan-AuNP
TABLE 1 | Efficacy of Kan-AuNPs against bacterial strains [µg/ml].
Bacterial Strain Kan MIC Kan-AuNPs MICa Fold change
S. bovis 512 9.8 52.2
S. epidermidis 64 6.3 10.2
E. aerogenes 64 5.6 11.4
P. aeruginosa PA01 50 6.7 7.5
P. aeruginosa UNC-D 140 3.3 42.4
Y. pestis CO92 5 1.7 2.9
Y. pestis CO92::Km 180 13.3 13.5
aMinimum inhibitory concentration (MIC) represents the concentration of Kan
present in the nanoparticles.
FIGURE 2 | Illustration of the morphological characterization of
synthesized citrate-AuNPs. The TEM micrograph shows the formation of
well-dispersed spherical citrate-AuNPs in the size range of 20 ± 5 nm. A core
size that is quite comparable to that of the Kan-AuNPs.
TABLE 2 | Efficacy of citrate-AuNPs compared to Kan-AuNPs [µg/mla].
Bacterial strain Citrate-AuNP MIC Kan-AuNPs MIC Fold change
S. bovis >600 18.2 >33
S. epidermidis >600 11.7 >51.3
E. aerogenes >600 10.4 >57.7
aMinimum inhibitory concentration (MIC) represents the concentration of Au
present in the nanoparticles.
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MICs were determined using the broth culture microdilution
method. As shown in Table 1, S. bovis, S. epidermidis, E. aerogenes
and P. aeruginosa PA01 were relatively resistant to Kan, with
MICs ranging from 50 to 512 µg/ml. Conversely, Y. pestis
CO92 was sensitive to Kan with an MIC of 4.8 µg/ml.
However, regardless of Kan sensitivity, when incubated with
Kan-AuNPs, the Kan MIC dramatically decreased for all
strains, with MICs <10 µg/ml Kan when conjugated to the
FIGURE 3 | Cytotoxicity of Kan-AuNPs. To measure the potential
cytotoxicity of Kan-AuNPs, Vero 76 cells were treated with increasing
concentrations of Kan-AuNPs (red) or Kan (blue) (n = 3). Twenty four hours
after addition of drug cell viability was determined using Alamar blue.
AuNPs (Table 1). Furthermore, these inhibitory concentrations
were also bactericidal, as determined by subculture onto non-
selective agar (data not shown). Next we examined whether
AuNP conjugation improved the efficacy of Kan against a
MDR P. aeruginosa (UNC-D) and a genetically engineered
Y. pestis Kan resistant strain (Y. pestis::Km). These strains
represent potential clinical isolates (UNC-D) or manipulated
biodefense species (Y. pestis::Km) that could be encountered
in the hospital. The MIC of Kan against these strains was
significantly higher than both P. aeruginosa PA01 and Y. pestis
CO92 (Table 1). However, as observed for the initial strains
we tested, conjugation to AuNPs decreased the MIC of Kan
against both strains, reducing the MICs by 13.50- and 42.40-
fold for Y. pestis::Km and P. aeruginosa UNC-D, respectively.
Importantly, in all cases conjugation to AuNPs improved
the MIC of Kan to within a range for aminoglycosides that
is considered sensitive by the CLSI guidelines (“M100-S25:
Performance Standards for Antimicrobial Susceptibility Testing;
Twenty-Fifth Informational Supplement” National Committee
for Clinical Laboratory Standards, 2015).
In addition to drug delivery capabilities, several studies have
suggested that AuNPs have inherent antimicrobial activities
(Zhou et al., 2012; Lima et al., 2013; Bindhu and Umadevi,
2014; Ortiz-Benitez et al., 2015) which may have contributed
to the decreased MIC of the Kan-AuNPs. To determine the
antimicrobial potential of AuNPs, we synthesized citrate-AuNPs
FIGURE 4 | Transmission electron microscope (TEM) images which visualize the morphological changes in bacteria upon treating with Kan-AuNPs at
different intervals of time. (A) Represents sequential images (from left to right) of Gram-positive, S. epidermidis bacteria treated with Kan-AuNPs (18.00 µg mL−1)
after 0, 6, and 12 h of incubation. (B) Represents sequential images (from left to right) of Gram-negative, E. aerogenes bacteria treated with Kan-AuNPs (16.00 µg
mL−1) after 0, 6, and 12 h of incubation. After 6 h of exposure, Kan-AuNPs were found to adhere and penetrate the bacterial cell wall which resulted in disruption of
cellular environment leading to lysis of cell due to leakage of cellular components as observed after 12 h of exposure. The results were similar for both Gram-positive
and Gram-negative bacteria.
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FIGURE 5 | Fluorescence images of Kan-AuNP induced cell membrane permeability using propidium iodide (PI) dye. Upper panel represents
Gram-positive bacteria, S. epidermidis, and lower panel represents Gram-negative bacteria, E. aerogenes. (A) For each image, the left half represents differential
interference contrast mode, while the right half represents the corresponding fluorescence image. Untreated samples of respective bacteria with Kan-AuNPs were
taken as control. (B) Represents a plot showing percentage permeability of S. epidermidis and E. aerogenes bacterial cells in presence and absence (Control) of
Kan-AuNPs. ∗∗∗∗∗p ≤ 0.00001 (Student’s t-test, two tailed assuming unequal variances).
of similar size to the Kan-AuNPs (20 ± 5 nm) (Figure 2). MICs
for the citrate-AuNPs were determined against S. epidermidis,
S. bovis and E. aerogenes. Unlike Kan-AuNPs, citrate-AuNPs
were not able to inhibit the growth of any of these strains
(MICs were >600 µg mL−1, which is at the dispersity limit
of the citrate-AuNPs) (Table 2). The surface zeta potential of
the citrate-AuNPs was determined to be −33.5 mV. While
this indicates a highly stable nanoparticle, the fact that the
electrostatic charge is negative may explain the high MIC
as the negative surface charge of the nanoparticle repels the
negatively charged surface of the bacterial membrane (Dickson
and Koohmaraie, 1989; Silhavy et al., 2010). Together these data
demonstrate that conjugation of Kan to AuNPs significantly
decreases the MIC of the antibiotic and that the increased efficacy
is independent from potential antimicrobial characteristics of the
AuNPs.
An effective antimicrobial needs to be inhibit bacterial growth
at a concentration lower than the tolerated dose of the drug.
One measure of tolerance is to determine the cytotoxicity of
the drug in tissue culture. Toward this end, Vero 76 cells
were treated with increasing concentrations of Kan-AuNPs
and cell viability was determined 24 h after treatment. The
concentration that resulted in a 50% decrease in viability (CC50)
was calculated to be 609.6 µg/ml. The in vitro CC50 of the
Kan-AuNPs is lower than Kan alone (Figure 3) but is >30-
fold higher than the average MIC of Kan-AuNPs against the
bacteria in (Table 1). The significantly lower MIC of Kan-AuNPs
compared to the CC50 suggests that the effective dose will be
lower than the minimum tolerated dose of the Kan-AuNPs
in vivo, and therefore, suitable for future preclinical studies,
especially against drug resistant bacteria that Kan alone is not
efficacious.
Kan-AuNPs Gain Entry into the Bacterial
Cytosol
Assuming AuNPs promote delivery of Kan to bacterial cells,
we would expect that Kan-AuNPs will associate and accumulate
with the bacteria during treatment. Furthermore, the positive
zeta potential of the Kan-AuNPs suggest that they may interact
with negatively charged membrane of bacteria (Torchilin, 2014;
Arakha et al., 2015). To track the localization of Kan-AuNPs,
a representative Gram-positive and Gram-negative bacterium,
S. epidermidis and E. aerogenes, respectively, were incubated
with Kan-GNPs and samples were harvested at 0, 6, and
12 h post-treatment and imaged by transmission electron
microscopy (TEM). For both bacteria, electron dense AuNPs
were observed to accumulate at the membrane and within the
cytosol (Figure 4). Furthermore, TEM images of later time
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points indicated compromised bacterial membrane integrity. To
confirm loss of membrane integrity, Kan-AuNP-treated bacteria
were incubated with propidium iodide (PI), a fluorescent dye
that intercalates into the DNA of bacteria, but is excluded
from bacteria with intact membranes. Fluorescence microscopy
showed that 75 ± 10% of bacteria co-localized with PI after
incubation with Kan-AuNPs, which was significantly higher
than bacteria incubated with the equivalent MIC dose of Kan
alone (Figure 5; p ≤ 0.00001). Together these data demonstrate
that Kan-AuNPs accumulate within the bacterial membrane and
cytoplasm, indicating that Kan-AuNPs are effectively delivered to
the bacterium and to a location where Kan can interact with the
protein synthesis machinery to directly inhibit bacterial growth.
CONCLUSION
The increase in community and nosocomial acquired infections
with drug resistant bacteria is a growing problem throughout
the world. While continued support for efforts to identify
novel antimicrobials is essential to combat these infections,
technologies to improve the efficacy of existing antibiotics is also
an important strategy to compliment the long and expensive
process of de novo drug discovery. Here, we demonstrate for the
first time an environmental friendly AuNP synthesis approach to
quickly and easily conjugate antibiotics to AuNPs. The benefits
of this approach include a synthesis methodology absent of
the use toxic organic solvent and a single-step methodology.
Furthermore, because of its simplicity, this synthesis approach
is amenable to Good Manufacturing Practices (GMP) and easily
scalable. Finally, as this process can use a wide variety of
functional groups to mediate the reducing and capping steps
in the synthesis, it is also applicable to the conjugation of
many different classes of antibiotics. Thus, we postulate that
this strategy will allow us to improve the efficacy of multiple
antibiotics against drug resistant bacteria.
Using Kan as a proof of concept for this approach, we
demonstrated that AuNP conjugation dramatically improved
the efficacy of the antibiotic against both Kan sensitive and
Kan resistant bacteria. Furthermore, we showed broad spectrum
improvement that impacted both Gram-negative and Gram-
positive bacteria. Importantly, the MICs that we observed were
below the CLSI breakpoint for Kan (“M100-S25: Performance
Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth
Informational Supplement” National Committee for Clinical
Laboratory Standards, 2015) and the CC50, strongly indicating
that Kan-AuNPs will be efficacious in vivo. The mechanism(s)
responsible for the increased activity is currently unknown.
However, accumulation of the Kan-AuNPs in the bacterial
membrane and within the bacterial cytosol indicates that the
AuNPs may facility entry across the bacterial membrane or
increase the local concentration of the antibiotic compared to
antibiotic alone. This local increase in concentration may be
enough to overcome resistance mechanisms. Alternatively, in
many bacteria, highlighted here by P. aeruginosa, drug eﬄux
pumps are a major mechanism of antibiotic resistance. It is
possible that conjugation to AuNPs inhibits the ability of these
systems to eﬄux the antibiotic, allowing the antibiotic to remain
within the bacteria in spite of these pumps. Finally, it is possible
that inhibition is a combination of antibiotic activity and cell
membrane disruption by the AuNPs. We are currently in the
process of better defining the mechanism(s) of increased Kan
efficacy. However, and importantly, our data indicate that the
conjugation process does not inactivate the Kan, as citrate-AuNPs
of similar size do not have comparable antimicrobial activity as
Kan-AuNPs. Therefore, regardless of the mechanism, it appears
to be dependent on conjugation to an active antibiotic.
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